文献速递神经与头颈病理细胞病理与分子病理

NTRK融合甲状腺癌与其他恶性融合甲状腺肿瘤的组织病理学特征比较

A comparison of the histopathologic features of thyroid carcinomas with NTRK fusions to those with other malignant fusions.
PubMed 文献 · Hum Pathol · 2024-06-08

本研究比较了NTRK融合甲状腺癌与其他恶性基因融合甲状腺肿瘤的临床病理特征。在55例甲状腺病变中,NTRK融合组22例,非NTRK融合组33例。NTRK融合组细针穿刺更多为Bethesda V类,组织学上侵袭性特征更常见,且复发时间更早,但多数患者无病生存。

要点

  • NTRK融合甲状腺癌细针穿刺常为Bethesda V类,非NTRK融合多为III类。
  • 两组组织学均以滤泡型甲状腺乳头状癌最常见,但NTRK组侵袭性特征更多。
  • NTRK融合组复发时间平均5.5个月,非NTRK组21个月,但多数患者无病生存。

核心结论

  • 携带恶性相关基因融合的甲状腺肿瘤多诊断为甲状腺乳头状癌的亚型/变异型。
  • NTRK融合甲状腺癌表现为滤泡型甲状腺乳头状癌,初诊时临床病理特征更具侵袭性,且可能更早复发。

研究设计与样本

  • 回顾性队列研究,检索2013至2023年病理档案中具有基因融合的甲状腺肿瘤,排除THADA融合和甲状腺髓样癌。
  • 共纳入55例甲状腺病变,其中NTRK融合组22例,非NTRK融合组33例。

主要发现

  • 细针穿刺细胞学:NTRK融合组54%为Bethesda V类,非NTRK融合组51.5%为Bethesda III类。
  • NTRK融合组最常见融合为ETV6::NTRK3,非NTRK融合组最常见为PAX8::PPAR-gamma。
  • 组织学上两组均以滤泡型甲状腺乳头状癌最常见,但NTRK融合组侵袭性特征更常见。
  • 局部区域复发:NTRK融合组2/22例,非NTRK融合组2/33例;平均手术至复发时间分别为5.5个月和21个月。
  • 两组大多数患者存活且无疾病证据。

临床怎么用

  • 对于细针穿刺诊断为Bethesda V类且组织学为滤泡型甲状腺乳头状癌的甲状腺肿瘤,应考虑NTRK融合可能。
  • NTRK融合甲状腺癌初诊时侵袭性特征更常见且复发更早,可能需要更密切的随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chromosomal rearrangements involving one of the NTRK genes result in oncogenic driver mutations in thyroid carcinoma (TC) and serve as a target for therapy. We compared the clinicopathologic features of thyroid carcinomas with NTRK fusions vs. thyroid neoplasms with other malignancy associated gene fusions within our institution. MATERIALS AND METHODS: Our pathology archives were searched from 2013 to 2023 for thyroid neoplasms with gene fusions, excluding THADA fusions and medullary thyroid carcinomas. RESULTS: 55 thyroid lesions were identified: 22 with NTRK fusions (NTRK cohort) and 33 with other fusions (non-NTRK cohort). On fine needle aspiration (FNA), 54% of the NTRK cohort were classified as Category V as per Bethesda System for Reporting Thyroid Cytology (TBSRTC) and 51.5% of non-NTRK cohort as TBSRTC Category III. In the NTRK cohort, the most common reported fusion was ETV6::NTRK3 and the most common reported fusion in the non-NTRK cohort was PAX8::PPAR-gamma. On histologic examination both cohorts were most commonly diagnosed as PTC follicular variant. Invasive features were more common in the NTRK cohort in comparison to the non-NTRK cohort. Locoregional recurrence occurred in 2/22 NTRK cases and 2/33 non-NTRK cases, with average time from surgery to recurrence being 5.5 months and 21 months, respectively. The majority of patients in both groups are alive with no evidence of disease. CONCLUSIONS: Thyroid neoplasms with a malignancy associated gene fusion are likely to be diagnosed as subtype/variant of PTC. Patients whose thyroid lesions harbor NTRK fusions present with a PTC-FV that on presentation has more aggressive clinicopathologic findings and are likely to have earlier disease recurrence.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Tondi Resta I, Rind A, Montone KT, et al. A comparison of the histopathologic features of thyroid carcinomas with NTRK fusions to those with other malignant fusions. Hum Pathol. 2024. PMID: 38857659. doi:10.1016/j.humpath.2024.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。